ConvaTec Group PLC (LON:CTEC) Receives GBX 318.67 Consensus Price Target from Analysts

Shares of ConvaTec Group PLC (LON:CTEC) have received a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is GBX 320.33.

Several analysts have weighed in on CTEC shares. JPMorgan Chase & Co. reissued an “overweight” rating on shares of ConvaTec Group in a report on Friday, November 14th. UBS Group reaffirmed a “buy” rating and set a GBX 375 price target on shares of ConvaTec Group in a research note on Friday, November 7th. Berenberg Bank increased their price objective on shares of ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research note on Thursday. Finally, Peel Hunt restated an “add” rating and set a GBX 270 target price on shares of ConvaTec Group in a report on Thursday, November 13th.

ConvaTec Group Stock Performance

CTEC opened at GBX 234 on Wednesday. ConvaTec Group has a 1-year low of GBX 219.80 and a 1-year high of GBX 311.20. The stock has a market cap of £4.56 billion, a P/E ratio of 22.08, a P/E/G ratio of 0.93 and a beta of 0.64. The stock’s 50 day simple moving average is GBX 236.08 and its 200 day simple moving average is GBX 237.77. The company has a debt-to-equity ratio of 85.32, a current ratio of 2.26 and a quick ratio of 0.96.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.